

Non-clinical studies of LMT801 for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)



NEUROLOGY	Preclinical
Product Type	Small molecules
Indication	Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Target	Oxido-reductase
MoA(Mechanism of Action)	Enhancement of NAD ⁺ level
Competitiveness	LMT801 provides a novel, first-in-class therapy for Charcot-Marie-Tooth Disease Type 1A, addressing a high unmet medical need with no approved treatments. By Enhancing NAD ⁺ levels through a reaction with Oxido-reductatse, LMT801 improves nerve function and coduction, promotes remyelination, and blocks axonal degeneration, as demonstrated by significant efficacy in preclinical models.
Development Stage	Preclinical
Route of Administration	Oral administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.